218 related articles for article (PubMed ID: 30152527)
1. Safety, tolerability, pharmacokinetics and pharmacokinetic-pharmacodynamic modelling of the novel H
Venail F; Attali P; Wersinger E; Gomeni R; Poli S; Schmerber S
Br J Clin Pharmacol; 2018 Dec; 84(12):2836-2848. PubMed ID: 30152527
[TBL] [Abstract][Full Text] [Related]
2. Management of peripheral vertigo with antihistamines: New options on the horizon.
Dyhrfjeld-Johnsen J; Attali P
Br J Clin Pharmacol; 2019 Oct; 85(10):2255-2263. PubMed ID: 31269270
[TBL] [Abstract][Full Text] [Related]
3. Effect of the novel histamine H
Petremann M; Gueguen C; Delgado Betancourt V; Wersinger E; Dyhrfjeld-Johnsen J
Br J Pharmacol; 2020 Feb; 177(3):623-633. PubMed ID: 31347148
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic-pharmacodynamic modelling of the antihistaminic (H1) effect of bilastine.
Jauregizar N; de la Fuente L; Lucero ML; Sologuren A; Leal N; Rodríguez M
Clin Pharmacokinet; 2009; 48(8):543-54. PubMed ID: 19705924
[TBL] [Abstract][Full Text] [Related]
5. Safety, Tolerability, Pharmacokinetics, Target Occupancy, and Concentration-QT Analysis of the Novel BTK Inhibitor Evobrutinib in Healthy Volunteers.
Becker A; Martin EC; Mitchell DY; Grenningloh R; Bender AT; Laurent J; Mackenzie H; Johne A
Clin Transl Sci; 2020 Mar; 13(2):325-336. PubMed ID: 31654487
[TBL] [Abstract][Full Text] [Related]
6. Safety, tolerability, pharmacokinetics, and pharmacodynamics of fimasartan following single and repeated oral administration in the fasted and fed states in healthy subjects.
Chi YH; Lee H; Paik SH; Lee JH; Yoo BW; Kim JH; Tan HK; Kim SL
Am J Cardiovasc Drugs; 2011 Oct; 11(5):335-46. PubMed ID: 21910510
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics, pharmacodynamics and safety of CEP-26401, a high-affinity histamine-3 receptor antagonist, following single and multiple dosing in healthy subjects.
Spiegelstein O; Stevens J; Van Gerven J; Nathan PJ; Maynard JP; Mayleben DW; Hellriegel E; Yang R
J Psychopharmacol; 2016 Oct; 30(10):983-93. PubMed ID: 27222271
[TBL] [Abstract][Full Text] [Related]
8. Single- and multiple-dose tolerability, safety, pharmacokinetics, and pharmacodynamics of the dual endothelin receptor antagonist aprocitentan in healthy adult and elderly subjects.
Sidharta PN; Melchior M; Kankam MK; Dingemanse J
Drug Des Devel Ther; 2019; 13():949-964. PubMed ID: 30962677
[TBL] [Abstract][Full Text] [Related]
9. The first selective VAP-1 inhibitor in China, TT-01025-CL: safety, tolerability, pharmacokinetics, and pharmacodynamics of single- and multiple-ascending doses.
Yang Y; Yu L; Sheng Z; Lin H; Weng Z; Song W; Cao B; Zhao Y; Gao Y; Ni S; Wang H; Ma T; Huang L; Sun C; Li J
Front Pharmacol; 2024; 15():1327008. PubMed ID: 38741586
[No Abstract] [Full Text] [Related]
10. A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects.
Taylor L; Gidal B; Blakey G; Tayo B; Morrison G
CNS Drugs; 2018 Nov; 32(11):1053-1067. PubMed ID: 30374683
[TBL] [Abstract][Full Text] [Related]
11. The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a TYK2/JAK1 Inhibitor (PF-06700841) in Healthy Subjects and Patients With Plaque Psoriasis.
Banfield C; Scaramozza M; Zhang W; Kieras E; Page KM; Fensome A; Vincent M; Dowty ME; Goteti K; Winkle PJ; Peeva E
J Clin Pharmacol; 2018 Apr; 58(4):434-447. PubMed ID: 29266308
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic-pharmacodynamic relationships of macitentan, a new endothelin receptor antagonist, after multiple dosing in healthy Korean subjects.
Ahn LY; Kim SE; Yi S; Dingemanse J; Lim KS; Jang IJ; Yu KS
Am J Cardiovasc Drugs; 2014 Oct; 14(5):377-85. PubMed ID: 24906252
[TBL] [Abstract][Full Text] [Related]
13. A new fully human recombinant FSH (follitropin epsilon): two phase I randomized placebo and comparator-controlled pharmacokinetic and pharmacodynamic trials.
Abd-Elaziz K; Duijkers I; Stöckl L; Dietrich B; Klipping C; Eckert K; Goletz S
Hum Reprod; 2017 Aug; 32(8):1639-1647. PubMed ID: 28591833
[TBL] [Abstract][Full Text] [Related]
14. Single and multiple dose evaluation of a novel MetAP2 inhibitor: Results of a randomized, double-blind, placebo-controlled clinical trial.
Malloy J; Zhuang D; Kim T; Inskeep P; Kim D; Taylor K
Diabetes Obes Metab; 2018 Aug; 20(8):1878-1884. PubMed ID: 29577550
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics, pharmacodynamics, and tolerance of single- and multiple-dose fexofenadine hydrochloride in healthy male volunteers.
Russell T; Stoltz M; Weir S
Clin Pharmacol Ther; 1998 Dec; 64(6):612-21. PubMed ID: 9871426
[TBL] [Abstract][Full Text] [Related]
16. Safety, Pharmacokinetics, and Pharmacodynamics of the Autotaxin Inhibitor GLPG1690 in Healthy Subjects: Phase 1 Randomized Trials.
van der Aar E; Desrivot J; Dupont S; Heckmann B; Fieuw A; Stutvoet S; Fagard L; Van de Wal K; Helmer E
J Clin Pharmacol; 2019 Oct; 59(10):1366-1378. PubMed ID: 31012984
[TBL] [Abstract][Full Text] [Related]
17. Safety and Pharmacokinetics of HRS-2261, a P2X3 Receptor Antagonist, in Healthy Subjects: A Randomized, Double-Blind, Placebo-Controlled Phase 1 Study.
Fan Y; Zhang X; Zhang Q; Zheng L; Zhou R; Sun C; Wang X; Song K; He Z; Wang H; Zhang Q; Hu W
Clin Pharmacokinet; 2024 Mar; 63(3):293-302. PubMed ID: 38198010
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics, pharmacodynamics, and tolerability of the dipeptidyl peptidase IV inhibitor LC15-0444 in healthy Korean men: a dose-block-randomized, double-blind, placebo-controlled, ascending single-dose, Phase I study.
Lim KS; Kim JR; Choi YJ; Shin KH; Kim KP; Hong JH; Cho JY; Shin HS; Yu KS; Shin SG; Kwon OH; Hwang DM; Kim JA; Jang IJ
Clin Ther; 2008 Oct; 30(10):1817-30. PubMed ID: 19014837
[TBL] [Abstract][Full Text] [Related]
19. Tolerability, Pharmacokinetic, and Pharmacodynamic Profiles of Henagliflozin, a Novel Selective Inhibitor of Sodium-Glucose Cotransporter 2, in Healthy Subjects Following Single- and Multiple-dose Administration.
Zhang YF; Liu YM; Yu C; Wang YT; Zhan Y; Liu HY; Zou JJ; Jia JY; Chen Q; Zhong DF
Clin Ther; 2021 Feb; 43(2):396-409. PubMed ID: 33454124
[TBL] [Abstract][Full Text] [Related]
20. Toreforant, an orally active histamine H
Boyle DL; DePrimo SE; Calderon C; Chen D; Dunford PJ; Barchuk W; Firestein GS; Thurmond RL
Inflamm Res; 2019 Apr; 68(4):261-274. PubMed ID: 30739130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
